Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study
Wienecke Buickhuisen, Sjaak Burgers, A. Vincent, C. Korse, R. van Klaveren, F.M.N.H. Schramel, N. Pavlakis, Anna Katherine Nowak, F.L. Custers, H. Schouwink, S.J. Gans, H. Groen, W. Strangkinga, Paul Baas
Dive into the research topics of 'Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study'. Together they form a unique fingerprint.